carbostyril has been researched along with Coronary Disease in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (50.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gluud, C; Hróbjartsson, A; Jakobsen, JC; Korang, SK; Safi, S; Sethi, NJ; Skoog, M | 1 |
| Barnett, AH; Knapp, M; L'Italien, GJ; Loze, JY; Millar, HL; van Baardewijk, M | 1 |
| Eriksson, J; Kasteng, F; Lindgren, P; Sennfält, K | 1 |
| Blonde, L; Gutterman, EM; Hanssens, L; Kan, HJ; Kim, MS; L'Italien, GJ; McQuade, RD | 1 |
1 review(s) available for carbostyril and Coronary Disease
| Article | Year |
|---|---|
Antibiotics for secondary prevention of coronary heart disease.
Topics: Anti-Bacterial Agents; Cardiovascular Diseases; Cause of Death; Coronary Disease; Death, Sudden, Cardiac; Humans; Macrolides; Middle Aged; Myocardial Infarction; Quinolones; Randomized Controlled Trials as Topic; Secondary Prevention; Stroke | 2021 |
2 trial(s) available for carbostyril and Coronary Disease
| Article | Year |
|---|---|
UK cost-consequence analysis of aripiprazole in schizophrenia: diabetes and coronary heart disease risk projections (STAR study).
Topics: Adolescent; Adult; Aged; Analysis of Variance; Antipsychotic Agents; Aripiprazole; Coronary Disease; Cost of Illness; Costs and Cost Analysis; Diabetes Mellitus; Female; Follow-Up Studies; Health Resources; Health Services; Humans; Male; Middle Aged; Piperazines; Prospective Studies; Quinolones; Risk Assessment; Risk Factors; Schizophrenia; United Kingdom; Young Adult | 2009 |
Predicted risk of diabetes and coronary heart disease in patients with schizophrenia: aripiprazole versus standard of care.
Topics: Adult; Algorithms; Aripiprazole; Blood Glucose; Body Mass Index; Cholesterol, HDL; Cholesterol, LDL; Comorbidity; Coronary Disease; Diabetes Mellitus; Female; Humans; Hypertension; Incidence; Male; Piperazines; Prevalence; Prospective Studies; Quinolones; Risk Assessment; Risk Factors; Schizophrenia | 2008 |
1 other study(ies) available for carbostyril and Coronary Disease
| Article | Year |
|---|---|
Metabolic effects and cost-effectiveness of aripiprazole versus olanzapine in schizophrenia and bipolar disorder.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Bipolar Disorder; Coronary Disease; Costs and Cost Analysis; Female; Humans; Male; Metabolic Diseases; Metabolism; Middle Aged; Olanzapine; Piperazines; Quality-Adjusted Life Years; Quinolones; Risk Assessment; Schizophrenia; Sweden | 2011 |